D-Index & Metrics Best Publications

Emiel J. Th. Rutgers

Antoni van Leeuwenhoek Hospital
Netherlands

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 86 Citations 38,733 299 World Ranking 9008 National Ranking 317

Overview

What is he best known for?

The fields of study Emiel J. Th. Rutgers is best known for:

Cancer
Osteoporosis
Relative risk

Emiel J. Th. Rutgers combines Oncology and Internal medicine in his studies. His Internal medicine study frequently links to related topics such as Adjuvant. His Adjuvant study typically links adjacent topics like Oncology. He performs integrative study on Breast cancer and Osteoporosis. He carries out multidisciplinary research, doing studies in Osteoporosis and Bone metastasis. In his research, he undertakes multidisciplinary study on Bone metastasis and Cancer. Emiel J. Th. Rutgers integrates several fields in his works, including Cancer and Breast cancer. His research on Family medicine frequently connects to adjacent areas such as Clinical Practice. His research combines Family medicine and Clinical Practice.

His most cited work include:

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (1043 citations)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (506 citations)

What are the main themes of his work throughout his whole career to date

His work in Quality of life (healthcare) covers topics such as Nursing which are related to areas like Patient satisfaction. The study of Breast-conserving surgery, Axillary Dissection and Prophylactic Mastectomy are components of his Mastectomy research. He merges Breast cancer with Carcinoma in his study. In his research, he performs multidisciplinary study on Carcinoma and Ductal carcinoma. He performs integrative study on Ductal carcinoma and Lobular carcinoma in his works. As part of his studies on Cancer, Emiel J. Th. Rutgers often connects relevant subjects like Prophylactic Mastectomy. Internal medicine connects with themes related to Lobular carcinoma in his study. Oncology and Adjuvant are frequently intertwined in his study. His study brings together the fields of Oncology and Adjuvant.

Emiel J. Th. Rutgers most often published in these fields:

Breast cancer (92.86%)
Cancer (92.86%)
Internal medicine (92.86%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

Marc J. van de Vijver;Yudong D. He;Laura J. van 't Veer;Hongyue Dai.
The New England Journal of Medicine (2002)

7499 Citations

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)

3457 Citations

Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition

Mieke Kriege;Cecile T.M. Brekelmans;Carla Boetes;Peter E. Besnard.
The New England Journal of Medicine (2004)

2066 Citations

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

Mila Donker;Geertjan van Tienhoven;Marieke E Straver;Philip Meijnen.
Lancet Oncology (2014)

1490 Citations

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Fatima Cardoso;Laura J. van’t Veer;Jan Bogaerts;Leen Slaets.
The New England Journal of Medicine (2016)

1443 Citations

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

Marc Buyse;Sherene Loi;Laura van't Veer;Giuseppe Viale.
Journal of the National Cancer Institute (2006)

1432 Citations

Association analysis identifies 65 new breast cancer risk loci

Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley.
Nature (2017)

969 Citations

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2017)

937 Citations

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

J. Bergh;K. Pritchard;K. Albain;S. Anderson.
The Lancet (2015)

671 Citations

Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial

Saskia Litière;Gustavo Werutsky;Ian S Fentiman;Emiel Rutgers.
Lancet Oncology (2012)

556 Citations

If you think any of the details on this page are incorrect, let us know.

Emiel J. Th. Rutgers

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Overview

What is he best known for?

The fields of study Emiel J. Th. Rutgers is best known for:

His most cited work include:

What are the main themes of his work throughout his whole career to date

Emiel J. Th. Rutgers most often published in these fields:

Best Publications

Report an issue

Frequent Co-Authors

Best Scientists Citing Emiel J. Th. Rutgers

Trending Scientists